General Mediterranean Holding SA (GMH) has long recognised the potential for the expansion of the pharmaceutical sector, a market worth around â‚¬620 billion annually.
Its recognition of the sectorâ€™s growing importance lies behind its decision to acquire a controlling interest in Hebi Misr Investment (HMI), an Egyptian-based holding company that engages through subsidiaries in the manufacture and marketing of a range of specialized pharmaceuticals, chemicals and hygiene products. HMI subsidiaries include Hebi Pharmaceutical Materials, a world-class facility specializing in the manufacture of Cephalosporin C and other antibiotics. Its products are exported to China, India, Jordan and Europe. Other subsidiaries are also involved in the production of antibiotics as well as in the manufacture and sale of high quality, non-woven fibre textiles to the hygiene and medicine sectors.
The acquisition of the UKâ€™s Anglian Pharmaceutical in 2006 added branded medicines manufacturing capabilities to the portfolio of over 200 generic licences owned by subsidiary Crescent Pharma, an established UK registered generic pharmaceutical company. Crescent Pharma was sold by GMH in 2009.
GMH also owns the London chain of pharmacies and retail outlets, Bliss Chemists.